Key result
Catheter-directed therapy improves the post-procedural right ventricular to left ventricular ratio and reduces the rate of bleeding episodes and all-cause mortality in patients with pulmonary embolism.
Why the study?
Data are lacking on clinical efficacy and safety outcomes, and large studies directly comparing catheter-directed therapy with systemic thrombolysis or surgical embolectomy in pulmonary embolism are absent.
Do systemic thrombolysis and catheter-directed therapy improve outcomes and reduce bleeding in patients with pulmonary embolism?
Do systemic thrombolysis and catheter-directed therapy improve outcomes and reduce bleeding in patients with pulmonary embolism?
Catheter-directed therapy is an emerging treatment for pulmonary embolism that improves right ventricular function with lower bleeding risks than systemic thrombolysis, though large comparative RCTs are still needed.
Answers are grounded in this paper and cite their sources.
Case report of CDT in PE is hypothesis-generating; leaves open need for RCTs on safety and outcomes.
Pulmonary embolism (PE) is the third most frequent cause of acute cardiovascular presentation after myocardial infarction and stroke. The treatment approach for PE consists of hemodynamic and respiratory support, anticoagulation, reperfusion treatment, and vena cava filters. Reperfusion treatment consists of systemic thrombolysis (recombinant tissue-type plasminogen activator, streptokinase, and urokinase); percutaneous catheter-directed therapy (CDT); and surgical embolectomy. CDT is an emerging treatment, with most data derived from randomized controlled trials (RCTs) or case series. Currently, there is a lack of data on clinical efficacy and safety outcomes and a lack of large studies that directly compare CDT with systemic thrombolysis or surgical embolectomy. This narrative review aims to explore the efficacy and safety of systemic thrombolysis and CDT in pulmonary embolism. Clinical trials have studied CDT for more than a decade now and have shown that CDT improves the post-procedural right ventricular (RV)/left ventricular (LV) ratio and has a reduced rate of bleeding episodes and all-cause mortality. However, there is a lack of large prospective RCTs studying the effects of CDT in intermediate-high-risk PE patients to determine which patients from this sub-group require CDT both in terms of improving short-term mortality risk and long-term morbidity (such as chronic thromboembolic pulmonary hypertension (CTEPH) and post-PE syndrome). Future clinical trials need to focus on identifying which patient groups will benefit from CDT over anticoagulation and if there are any advantages of using the EkoSonic endovascular system (EKOS) (ultrasound (US)-assisted CDT) over standard CDT. In addition, the scientific community needs to study the healthcare costs of CDT over traditional treatment, which is relevant for public health systems such as the National Health Service (NHS). Lastly, we need standardized guidelines for the use of thrombectomy systems since pulmonary embolism is a complex disease requiring a multifaceted and nuanced treatment approach.
No takes yet. Share an insight, caveat, or question.
Upadhyay et al. (2024) conducted a review in Pulmonary embolism. Catheter-directed therapy and systemic thrombolysis vs. Anticoagulation or standard care was evaluated on Efficacy (RV/LV ratio improvement, mortality) and safety (bleeding episodes). Catheter-directed therapy improves the post-procedural right ventricular to left ventricular ratio and reduces the rate of bleeding episodes and all-cause mortality in patients with pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: